NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through strategic collaborations and research agreements. Its lead clinical candidate is indiplon, a non-benzodiazepine for the treatment of insomnia, developed in collaboration with Pfizer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by $53.9 million (39%) from 2003 to 2004. This was primarily driven by a $69.2 million reduction in sponsored development revenue from the Pfizer collaboration as the Phase III indiplon program wound down, partially offset by $20.5 million in milestone payments earned for successful Phase III study completion.
• Expense Reduction: R&D expenses decreased by $62.2 million to $115.1 million, largely due to the tapering of external development costs for indiplon ($84.9 million decrease), offset by increased costs in other clinical programs and personnel.
• Increased Net Loss: Despite lower R&D spend, the net loss increased by $15.5 million due to higher non-indiplon development costs and increased employee/laboratory expenses.
• Cash Position: Cash and investments decreased by $152.1 million, attributed to a $50.0 million cash payment to Wyeth to acquire their financial interest in indiplon, a reduction in clinical trial payables, and the net operating loss.
• Debt Restructuring: The company repaid a $60.3 million construction loan in October 2004 and replaced it with a $49.5 million long-term mortgage loan secured by its new corporate facility.

Guidance, Outlook, and Risks

• Regulatory Status (Indiplon): In December 2004, the FDA did not accept the New Drug Application (NDA) for indiplon immediate release (IR) due to technical difficulties with electronic navigation (not content-related). The company voluntarily withdrew the modified release (MR) NDA to address similar issues. Management plans to refile the IR NDA in Q1/Q2 2005 and the MR NDA in Q2 2005.
• Profitability Outlook: Management does not expect to be profitable from product sales or royalties in 2005. The company anticipates continued operating losses and negative cash flow as it advances other pipeline candidates and builds a sales force.
• Sales Force: Beginning in 2005, Pfizer is obligated to fund a 200-person Neurocrine sales force to co-promote indiplon and Pfizer's Zoloft. Neurocrine expects to hire regional managers in Q1 2005 and have the full force in place by July 2005.
• Key Risks:
  • Regulatory Approval: Failure to successfully refile and gain FDA approval for indiplon would severely harm the business.
  • Collaboration Dependence: Heavy reliance on Pfizer for funding, development, and commercialization of indiplon; Pfizer may terminate the agreement with 180 days' notice.
  • Liquidity: While current resources are sufficient for 12 months, the company may require additional funding for future R&D and commercialization.
  • Accounting Changes: Adoption of SFAS 123R (Share-Based Payment) in 2005 will require expensing stock options, significantly impacting reported net loss.

Investor Verification Checklist

• Indiplon NDA Refiling: Verify the successful resubmission of the IR and MR NDAs to the FDA in early 2005 and the timeline for FDA review.
• Pfizer Collaboration Status: Monitor for any announcements regarding the termination or modification of the Pfizer agreement, which is critical for funding and commercialization.
• Wyeth Transaction Impact: Confirm the amortization schedule of the $95 million Wyeth royalty stream acquisition and its impact on future royalty obligations.
• Sales Force Deployment: Track the hiring progress of the 200-person sales force and the associated costs funded by Pfizer.
• Stock-Based Compensation: Review Q1 2005 financials for the impact of SFAS 123R adoption on net loss and cash flow classification.